Hodgkin's lymphoma is a relatively uncommon malignancy that predominantly effects young adults. It became the first human cancer to be cured with combination chemotherapy. Unfortunately, many cured patients do not live their expected lifespan because of long-term lethal effects of therapy. Novel treatment strategies based on our understanding of Hodgkin's lymphoma biology are currently being explored to maintain the high cure rate without the added treatment related toxicity.